Carnegie Mellon and Yale Study in Mice Shows Promise for Treating Genetic Conditions During Early Stages of Development
Researchers at Carnegie Mellon University and Yale University have for the first time used a gene editing technique to successfully cure a genetic condition in utero in a mouse model. Their findings, published in Nature Communications, present a promising new avenue for research into treating genetic conditions during fetal development.
An estimated 8 million children are born each year with severe genetic disorders or birth defects. Genetic conditions can often be detected during pregnancy using amniocentesis, but there are no treatment options to correct these genetic conditions before birth.
“Early in embryonic development, there are a lot of stem cells dividing at a rapid pace. If we can go in and correct a genetic mutation early on, we could dramatically reduce the impact the mutation has on fetal development or even cure the condition,” said Danith Ly, professor of chemistry in Carnegie Mellon’s Mellon College of Science.
In this study, the researchers used a peptide nucleic acid-based gene editing technique that they had previously used to cure beta thalassemia, a genetic blood disorder that results in the reduced production of hemoglobin, in adult mice.
Peptide nucleic acids are synthetic molecules that combine a synthetic protein backbone with the nucleobases found in DNA and RNA. The PNAs used in this study were created by Ly at Carnegie Mellon’s Center for Nucleic Acids Science and Technology (CNAST), a leading center for PNA science.
Their technique uses an FDA-approved nanoparticle to deliver PNA molecules paired with donor DNA to the site of a genetic mutation. When the PNA-DNA complex identifies a designated mutation, the PNA molecule binds to the DNA and unzips its two strands. The donor DNA binds with the faulty DNA and spurs the cell’s DNA repair pathways into action, allowing it to correct the error.
In the current study, the researchers used a technique similar to amniocentesis to inject the PNA complex into the amniotic fluid of pregnant mice whose fetuses carried a mutation in the beta-globin gene that causes beta thalassemia.
With just one injection of the PNA during gestation, the researchers were able to correct 6 percent of the mutations. This 6 percent correction was enough to cause dramatic improvements in the mice’s symptoms of beta thalassemia – and enough for the mice to be considered cured. Mice that were treated using PNA while in utero had levels of hemoglobin that were within the normal range, less spleen enlargement and increased survival rates.
The researchers also noted that there were no off-target effects from the treatment, a finding that might suggest this method would be preferable over other gene editing techniques like CRISPR/Cas9, which can erroneously damage off-target DNA.
“CRISPR is much easier to use, which makes it ideal for laboratory research. But the off-site errors make it less useful for therapeutics,” said Ly. “The PNA technique is more ideal for therapeutics. It doesn’t cut the DNA, it just binds to it and repairs things that seem unusual. We looked at 50 million samples and couldn’t find one offsite error when we used our PNA gene editing technique.”
The researchers believe that their technique might be able to achieve even higher success rates if they can administer it multiple times during gestation. They also hope to see if their technique can be applied to other conditions .
The Latest on: Curing a genetic condition in utero
via Google News
The Latest on: Curing a genetic condition in utero
- 'We had James to save our sick son's life'on October 3, 2021 at 4:59 pm
James Harry Whitaker was delivered by caesarean section at 9.25am on June 16 and cried when he was taken from his mother's womb. His parents ... tissue match can cure him. He already has a ...
- Gene link to female infertility diseaseon September 25, 2021 at 5:00 pm
Scientists have found a genetic link to a painful ... women in Britain have the disease, which causes agonising abdominal pain and has no known complete cure. Around one-third have reported ...
- Heart Hope: Announcing the Encouraging Results of a Cell-Therapy Clinical Study by Longeveronon September 16, 2021 at 9:11 am
Researchers in the medical field are constantly working to create medicines to prevent and cure diseases ... for a life-threatening congenital condition called hypoplastic left heart syndrome ...
- Endometriosis: Gene identified which could be potential treatment target – new studyon September 11, 2021 at 12:29 am
Endometriosis is the second most common gynaecological condition in the UK, and is thought to affect 10% of women worldwide. Endometriosis occurs when tissue similar to that lining the womb is ...
- Scientists identify the genes that cause endometriosis, giving hope for a new treatmenton September 9, 2021 at 9:54 am
The condition is chronic, extremely painful and can result in infertility. Endometriosis happens when tissue similar to the lining of the womb (the endometrium) grows outside of the womb ...
- Endometriosis: gene identified which could be potential treatment target – new studyon September 6, 2021 at 6:40 am
The condition is chronic, extremely painful, and can result in infertility. Endometriosis happens when tissue similar to the lining of the womb (the ... there's no cure. While treatments such ...
via Bing News